New! Sign up for our free email newsletter.
Science News
from research organizations

Novel therapy for Crimean-Congo hemorrhagic fever virus

Date:
June 1, 2021
Source:
US Army Medical Research Institute of Infectious Diseases
Summary:
Scientists have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.
Share:
FULL STORY

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected. Their results are published online today in the journal Cell.

Using blood samples donated by disease survivors, the study's authors characterized the human immune response to natural CCHFV infection. They were able to identify several potent neutralizing antibodies that target the viral glycoprotein -- a component of the virus that plays a key role in disease development. Several of these antibodies, administered individually or in combination, protected mice from CCHFV when given prior to virus exposure.

To treat mice that had already been infected, the team created "bispecific" antibodies that combined potency with the ability to bind to two separate sites on the CCHFV glycoprotein. One of these bispecific antibodies, called DVD-121-801, overcame CCHFV infection in mice with just a single dose administered 24 hours after challenge with live virus.

Efforts are underway to develop DVD-121-801 as a potential therapeutic for human patients, according to co-first author Andrew H. Herbert, Ph.D., of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

CCHFV is the most prevalent tick-borne virus that causes human disease, and is endemic in countries across Europe, Asia, and Africa. Despite its high lethality and widespread distribution, no vaccines or specific treatments are available. It has been designated a priority pathogen by the World Health Organization.

"Rodent models of CCHFV infection are useful in testing and down-selecting neutralizing antibodies," commented Herbert. "However, to advance a lead candidate for therapeutic use, it will be necessary to conduct studies in larger animal models that more faithfully recapitulate human disease."


Story Source:

Materials provided by US Army Medical Research Institute of Infectious Diseases. Note: Content may be edited for style and length.


Journal Reference:

  1. J. Maximilian Fels, Daniel P. Maurer, Andrew S. Herbert, Ariel S. Wirchnianski, Olivia Vergnolle, Robert W. Cross, Dafna M. Abelson, Crystal L. Moyer, Akaash K. Mishra, Jennifer T. Aguilan, Ana I. Kuehne, Noel T. Pauli, Russell R. Bakken, Elisabeth K. Nyakatura, Jan Hellert, Gregory Quevedo, Leslie Lobel, Stephen Balinandi, Julius J. Lutwama, Larry Zeitlin, Thomas W. Geisbert, Felix A. Rey, Simone Sidoli, Jason S. McLellan, Jonathan R. Lai, Zachary A. Bornholdt, John M. Dye, Laura M. Walker, Kartik Chandran. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021; DOI: 10.1016/j.cell.2021.05.001

Cite This Page:

US Army Medical Research Institute of Infectious Diseases. "Novel therapy for Crimean-Congo hemorrhagic fever virus." ScienceDaily. ScienceDaily, 1 June 2021. <www.sciencedaily.com/releases/2021/06/210601165104.htm>.
US Army Medical Research Institute of Infectious Diseases. (2021, June 1). Novel therapy for Crimean-Congo hemorrhagic fever virus. ScienceDaily. Retrieved October 31, 2024 from www.sciencedaily.com/releases/2021/06/210601165104.htm
US Army Medical Research Institute of Infectious Diseases. "Novel therapy for Crimean-Congo hemorrhagic fever virus." ScienceDaily. www.sciencedaily.com/releases/2021/06/210601165104.htm (accessed October 31, 2024).

Explore More

from ScienceDaily

RELATED STORIES